Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease–Induced Congestive Heart Failure or Myocardial Infarction

(2009) Akash Nanda   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes

(2009) Shabbir M.H. Alibhai et al.   JOURNAL OF CLINICAL ONCOLOGY

Duration of Androgen Suppression in the Treatment of Prostate Cancer

(2009) Michel Bolla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer

(2008) Matthew R. Smith et al.   CANCER

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer

(2008) Anthony V. D'Amico et al.   CANCER

Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02

(2008) Jason A. Efstathiou et al.   EUROPEAN UROLOGY

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

(2008) Mack Roach et al.   JOURNAL OF CLINICAL ONCOLOGY

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

(2008) Eric M. Horwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

(2008) Jason A. Efstathiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

(2008) Matthew R. Smith et al.   UROLOGY